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oxidized peptide 1 ( Figure S7 ). Figure S5 . HPLC chromatograms of (a) peptide 1 (1.0 mg/mL, 1.5 mL) after stirring for 30 min; (b) supernatant from the reaction of SiO2@TPEA@Pt(IV) (50 mg) with peptide 1 (1.0 mg/mL, 1.5 mL) for 30 min; and (c) mixture from the reaction of [Pt(en)2Cl2]Cl2 (1.8 mg) with peptide 1 (1.0 mg/mL, 1.5 mL). 
HPLC and ESI-MS characterization of peptide 2
Peptide 2 was dissolved in a pH 4.5 buffer (1 mg/mL, 1.5 mL) and stirred at 25 °C for 80 min. The mixture was then analyzed by an HPLC system equipped with a UV-vis detector at 215 nm using a 250 mm × 4.6 mm C8 column at a flow rate of 1.0 mL/min at room temperature. The HPLC solvent consisted of solvent A (0.1% TFA in acetonitrile) and solvent B (0.1% TFA in water). The elution protocol for analytical HPLC started with 90% B, followed by a linear gradient to 70% B over 22 min. The HPLC chromatogram obtained is shown in Figure S8a .
Next, to the mixture of peptide 2 in a pH 4.5 buffer (1 mg/mL, 1.5 mL), SiO2@TPEA@Pt(IV) (7.5 mg) or [Pt(en)2Cl2]Cl2 (0.9 mg) were added with stirring at 25 °C for 80 min. The supernatant obtained after centrifugation in the former case and the reaction mixture in the latter case were analyzed using the HPLC method described above. The HPLC chromatograms obtained for the two cases are presented in Figure S8b and S8c, respectively.
Peptide 2 as well as its oxidation product were also characterized by ESI-MS in Figure S10 . MS of oxidized peptide 2.
HPLC and ESI-MS characterization of reduced arginine vasopressin
Reduced arginine vasopressin was dissolved in a pH 4.5 buffer (2 mg/mL, 1.5 mL) and stirred at 25 °C for 30 min. The mixture was then analyzed using HPLC equipped with a UV-vis detector at 215 nm with a 250 mm × 4.6 mm C8 column at a flow rate of 1.0 mL/min at room temperature. The HPLC elution solvent consisted of 20% solvent A (0.03% TFA in acetonitrile) and 80% solvent B (0.03% TFA in water). The HPLC chromatogram obtained is shown in Figure S11a .
Next, reduced arginine vasopressin was dissolved in a pH 4.5 buffer (2 mg/mL, 1.5 mL) and reacted with SiO2@TPEA@Pt(IV) (50 mg) or [Pt(en)2Cl2]Cl2 (1.7 mg)
under stirring at 25 °C for 30 min. In the former case, the mixture was subjected to centrifugation and the supernatant obtained was analyzed using HPLC ( Figure S11b ).
In the latter case, the reaction mixture was analyzed by HPLC ( Figure S11c 
HPLC and ESI-MS characterization of reduced iRGD (a disulfide-based cyclic RGD peptide, c(CRGDKGPDC)) peptide
Reduced iRGD peptide was dissolved in a pH 4.5 buffer (2 mg/mL, 1.2 mL) and stirred at 25 °C for 30 min. The solution was analyzed by a gradient HPLC equipped with a UV-vis detector at 215 nm using a 250 mm × 4.6 mm C8 column at a flow rate of 1.0 mL/min at room temperature. The HPLC solvent consisted of solvent A (0.1% TFA in acetonitrile) and solvent B (0.1% TFA in water). The elution protocol for analytical HPLC started with 95% B, followed by a linear gradient to 92% B over 20 min, and back to 95% over 5 min. The HPLC chromatogram obtained is shown in Figure S14a .
Next, the reduced iRGD peptide was dissolved in a pH 4.5 buffer (2 mg/mL, 1.2 mL) and reacted with SiO2@TPEA@Pt(IV) (40 mg) or [Pt(en)2Cl2]Cl2 (1.5 mg)
under stirring at 25 °C for 30 min. In the former case, the supernatant was obtained after centrifugation and analyzed using HPLC, whereas in the latter case, the reaction mixture was analyzed using HPLC with the conditions described above. The results are shown in Figure S14b and Figure 
HPLC and ESI-MS characterization of reduced oxytocin
Reduced oxytocin was dissolved in a pH 4.5 buffer (2 mg/mL, 1.2 mL) and stirred at 25 °C for 30 min. The solution was then analyzed by a gradient HPLC equipped with a UV-vis detector at 215 nm using a 250 mm × 4.6 mm C8 column at a flow rate of 1.0 mL/min at room temperature. The HPLC solvent was composed of solvent A (0.03% TFA in acetonitrile) and solvent B (0.03% TFA in water). The elution protocol for analytical HPLC started with 90% B, followed by a linear gradient to 25% B over 10 min, and further to 50% B over 10 min, held at 50% B for 5 min, continued to 90%
B over 20 min, and finally returned to 90% over 10 min. The HPLC chromatogram obtained is shown in Figure S17a .
Next, reduced oxytocin was dissolved in a pH 4.5 buffer (2 mg/mL, 1.2 mL) and reacted with SiO2@TPEA@Pt(II) (40 mg) or SiO2@TPEA@Pt(IV) (40 mg) under stirring at 25 °C for 30 min. After centrifugation of the mixture, the supernatants obtained were analyzed using the same HPLC method as described above. The HPLC chromatogram obtained is shown in Figure S17b and S17c.
Reduced oxytocin was then dissolved in pH 4.5 buffer (2 mg/mL, 1.2 mL) and reacted with [Pt(en)2Cl2]Cl2 (1.5 mg) at 25 °C for 30 min. The mixture was analyzed using the HPLC method described above, and the result is shown in Figure S17d . 
HPLC and ESI-MS characterization of reduced somatostatin
Reduced somatostatin was dissolved in a solution containing pH 4.5 buffer and acetonitrile (3:1 v/v) (1 mg/mL, 2 mL) and stirred at 25 °C for 30 min. The solution was then analyzed by a gradient HPLC equipped with a UV-vis detector at 215 nm using a 250 mm × 4.6 mm C8 column at a flow rate of 1.0 mL/min at room temperature. The HPLC solvent mixture consisted of solvent A (0.1% TFA in acetonitrile) and solvent B (0.1% TFA in water). The elution protocol for the HPLC analysis started with 70% B, followed by a linear gradient to 0% B over 15 min, and returned to 70% over 5 min. The HPLC chromatogram obtained is shown in Figure S20a .
Next, reduced somatostatin solution (1 mg/mL, 2 mL) was reacted with SiO2@TPEA@Pt(IV) (25 mg) or [Pt(en)2Cl2]Cl2 (1.0 mg) under stirring at 25 °C for 30 min. In the former case, the mixture was subjected to centrifugation and the supernatant obtained was analyzed using HPLC. In the latter case, the reaction mixture was analyzed using HPLC. The conditions described above were used for the HPLC analyses, and the results for the two cases are shown in Figure S20b and Figure   S20c , respectively. 
HPLC analysis of the interaction of oxytocin with SiO 2 @TPEA@Pt(II)
Reduced oxytocin was dissolved in pH 4.5 buffer (2 mg/mL, 3.3 mL) and reacted with 4.4 mg of [Pt(en)2Cl2]Cl2 for 30 min. The mixture was then analyzed by HPLC using the protocol described in section 3.5. The HPLC chromatogram is shown in Figure S23a . Further, the above solution (1.2 mL) was mixed with 40 mg of SiO2@TPEA@Pt(II) under stirring for 30 min. The mixture was centrifuged, and the supernatant was analyzed by HPLC. The result is shown in Figure S23b . SiO2@TPEA@Pt(II) with 1.2 mL of (a) for 30 min.
